Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Oct;41(10):2165–2172. doi: 10.1128/aac.41.10.2165

In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.

F Biavasco 1, C Vignaroli 1, R Lupidi 1, E Manso 1, B Facinelli 1, P E Varaldo 1
PMCID: PMC164087  PMID: 9333042

Abstract

LY333328 is a semisynthetic N-alkyl derivative of LY264826, a naturally occurring structural analog of vancomycin. LY333328 was evaluated for its in vitro inhibitory and bactericidal activities in comparison with those of the two currently available glycopeptides (vancomycin and teicoplanin). Glycopeptide-susceptible test strains included a total of 311 isolates (most of clinical origin) from the genera Staphylococcus, Enterococcus, Streptococcus, Aerococcus, Gemella, Lactococcus, Listeria, Corynebacterium, and Clostridium. Test strains resistant or intermediate to vancomycin and/or teicoplanin included 56 clinical isolates of Enterococcus (of the VanA, VanB, and VanC phenotypes) and 32 clinical isolates of Staphylococcus (S. haemolyticus, S. epidermidis, and S. aureus), 31 strains of gram-positive genera outside the spectrum of activity of vancomycin (Leuconostoc, Pediococcus, Lactobacillus, and Erysipelothrix), and laboratory-derived organisms obtained after exposure of susceptible Staphylococcus isolates to teicoplanin (6 strains) or laboratory-derived organisms with resistance determinants received from VanA enterococci (2 Enterococcus and 25 Listeria transconjugants). LY333328 was highly active against staphylococci, enterococci, and listeriae (whether they were clinical or laboratory-derived strains) resistant to the currently available glycopeptides. In particular, the MICs of LY333328 did not vary substantially between teicoplanin-susceptible and teicoplanin-resistant staphylococci and between vancomycin-susceptible and vancomycin-resistant enterococci. LY333328 demonstrated fairly good inhibitory activity even against most strains of Leuconostoc, Pediococcus, and Erysipelothrix (MIC range, 1 to 8 microg/ml), whereas it proved less active (although much more active than vancomycin or teicoplanin) against Lactobacillus strains. In minimal bactericidal concentration (MBC) and time-kill studies, LY333328 demonstrated excellent bactericidal activity; enterococci, in particular, which were largely tolerant of vancomycin and teicoplanin, were uniformly killed by LY333328, with MBC-to-MIC ratios of 4 to 8 for most vancomycin-susceptible and vancomycin-resistant strains. In attempts to select for resistant clones, no survivors stably growing in the presence of 10 microg of LY333328 per ml were obtained from the Staphylococcus and Enterococcus test strains exposed to the drug.

Full Text

The Full Text of this article is available as a PDF (241.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arioli V., Pallanza R. Teicoplanin-resistant coagulase-negative staphylococci. Lancet. 1987 Jan 3;1(8523):39–39. doi: 10.1016/s0140-6736(87)90724-0. [DOI] [PubMed] [Google Scholar]
  2. Biavasco F., Giovanetti E., Miele A., Vignaroli C., Facinelli B., Varaldo P. E. In vitro conjugative transfer of VanA vancomycin resistance between Enterococci and Listeriae of different species. Eur J Clin Microbiol Infect Dis. 1996 Jan;15(1):50–59. doi: 10.1007/BF01586185. [DOI] [PubMed] [Google Scholar]
  3. Biavasco F., Giovanetti E., Montanari M. P., Lupidi R., Varaldo P. E. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. J Antimicrob Chemother. 1991 Jan;27(1):71–79. doi: 10.1093/jac/27.1.71. [DOI] [PubMed] [Google Scholar]
  4. Biavasco F., Lupidi R., Varaldo P. E. In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873. Antimicrob Agents Chemother. 1992 Feb;36(2):331–338. doi: 10.1128/aac.36.2.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Biavasco F., Miele A., Vignaroli C., Manso E., Lupidi R., Varaldo P. E. Genotypic characterization of a nosocomial outbreak of VanA Enterococcus faecalis. Microb Drug Resist. 1996 Summer;2(2):231–237. doi: 10.1089/mdr.1996.2.231. [DOI] [PubMed] [Google Scholar]
  6. Cohen M. L. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science. 1992 Aug 21;257(5073):1050–1055. doi: 10.1126/science.257.5073.1050. [DOI] [PubMed] [Google Scholar]
  7. Cooper R. D., Snyder N. J., Zweifel M. J., Staszak M. A., Wilkie S. C., Nicas T. I., Mullen D. L., Butler T. F., Rodriguez M. J., Huff B. E. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot (Tokyo) 1996 Jun;49(6):575–581. doi: 10.7164/antibiotics.49.575. [DOI] [PubMed] [Google Scholar]
  8. Dutka-Malen S., Blaimont B., Wauters G., Courvalin P. Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother. 1994 Jul;38(7):1675–1677. doi: 10.1128/aac.38.7.1675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Facinelli B., Giovanetti E., Varaldo P. E., Casolari P., Fabio U. Antibiotic resistance in foodborne Listeria. Lancet. 1991 Nov 16;338(8777):1272–1272. doi: 10.1016/0140-6736(91)92138-r. [DOI] [PubMed] [Google Scholar]
  10. Fontana R., Ligozzi M., Pedrotti C., Padovani E. M., Cornaglia G. Vancomycin-resistant Bacillus circulans carrying the vanA gene responsible for vancomycin resistance in enterococci. Eur J Clin Microbiol Infect Dis. 1997 Jun;16(6):473–474. doi: 10.1007/BF02471915. [DOI] [PubMed] [Google Scholar]
  11. French G., Abdulla Y., Heathcock R., Poston S., Cameron J. Vancomycin resistance in south London. Lancet. 1992 Mar 28;339(8796):818–819. doi: 10.1016/0140-6736(92)91954-7. [DOI] [PubMed] [Google Scholar]
  12. Handwerger S., Pucci M. J., Kolokathis A. Vancomycin resistance is encoded on a pheromone response plasmid in Enterococcus faecium 228. Antimicrob Agents Chemother. 1990 Feb;34(2):358–360. doi: 10.1128/aac.34.2.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Leclercq R., Derlot E., Duval J., Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988 Jul 21;319(3):157–161. doi: 10.1056/NEJM198807213190307. [DOI] [PubMed] [Google Scholar]
  14. Leclercq R., Derlot E., Weber M., Duval J., Courvalin P. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob Agents Chemother. 1989 Jan;33(1):10–15. doi: 10.1128/aac.33.1.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Manso E., De Sio G., Biavasco F., Varaldo P. E., Sambo G., Maffei C. Vancomycin-resistant enterococci. Lancet. 1993 Sep 4;342(8871):616–617. [PubMed] [Google Scholar]
  16. Moellering R. C., Jr The Garrod Lecture. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother. 1991 Jul;28(1):1–12. doi: 10.1093/jac/28.1.1. [DOI] [PubMed] [Google Scholar]
  17. Murray B. E. What can we do about vancomycin-resistant enterococci? Clin Infect Dis. 1995 May;20(5):1134–1136. doi: 10.1093/clinids/20.5.1134. [DOI] [PubMed] [Google Scholar]
  18. Nagarajan R. Antibacterial activities and modes of action of vancomycin and related glycopeptides. Antimicrob Agents Chemother. 1991 Apr;35(4):605–609. doi: 10.1128/aac.35.4.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nagarajan R. Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J Antibiot (Tokyo) 1993 Aug;46(8):1181–1195. doi: 10.7164/antibiotics.46.1181. [DOI] [PubMed] [Google Scholar]
  20. Nicas T. I., Cole C. T., Preston D. A., Schabel A. A., Nagarajan R. Activity of glycopeptides against vancomycin-resistant gram-positive bacteria. Antimicrob Agents Chemother. 1989 Sep;33(9):1477–1481. doi: 10.1128/aac.33.9.1477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nicas T. I., Mullen D. L., Flokowitsch J. E., Preston D. A., Snyder N. J., Zweifel M. J., Wilkie S. C., Rodriguez M. J., Thompson R. C., Cooper R. D. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob Agents Chemother. 1996 Sep;40(9):2194–2199. doi: 10.1128/aac.40.9.2194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Noble W. C., Virani Z., Cree R. G. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. 1992 Jun 1;72(2):195–198. doi: 10.1016/0378-1097(92)90528-v. [DOI] [PubMed] [Google Scholar]
  23. Poyart C., Pierre C., Quesne G., Pron B., Berche P., Trieu-Cuot P. Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis. Antimicrob Agents Chemother. 1997 Jan;41(1):24–29. doi: 10.1128/aac.41.1.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schwalbe R. S., Stapleton J. T., Gilligan P. H. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med. 1987 Apr 9;316(15):927–931. doi: 10.1056/NEJM198704093161507. [DOI] [PubMed] [Google Scholar]
  25. Shlaes D. M., Bouvet A., Devine C., Shlaes J. H., al-Obeid S., Williamson R. Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256. Antimicrob Agents Chemother. 1989 Feb;33(2):198–203. doi: 10.1128/aac.33.2.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Shlaes D. M. Vancomycin-resistant bacteria. Infect Control Hosp Epidemiol. 1992 Apr;13(4):193–194. doi: 10.1086/646508. [DOI] [PubMed] [Google Scholar]
  27. Spera R. V., Jr, Farber B. F. Multiply-resistant Enterococcus faecium. The nosocomial pathogen of the 1990s. JAMA. 1992 Nov 11;268(18):2563–2564. [PubMed] [Google Scholar]
  28. Uttley A. H., Collins C. H., Naidoo J., George R. C. Vancomycin-resistant enterococci. Lancet. 1988 Jan 2;1(8575-6):57–58. doi: 10.1016/s0140-6736(88)91037-9. [DOI] [PubMed] [Google Scholar]
  29. Uttley A. H., George R. C., Naidoo J., Woodford N., Johnson A. P., Collins C. H., Morrison D., Gilfillan A. J., Fitch L. E., Heptonstall J. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect. 1989 Aug;103(1):173–181. doi: 10.1017/s0950268800030478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Van der Auwera P., Pensart N., Korten V., Murray B. E., Leclercq R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis. 1996 May;173(5):1129–1136. doi: 10.1093/infdis/173.5.1129. [DOI] [PubMed] [Google Scholar]
  31. Varaldo P. E., Debbia E., Schito G. C. In vitro activity of teichomycin and vancomycin alone and in combination with rifampin. Antimicrob Agents Chemother. 1983 Mar;23(3):402–406. doi: 10.1128/aac.23.3.402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Venditti M., Biavasco F., Varaldo P. E., Macchiarelli A., De Biase L., Marino B., Serra P. Catheter-related endocarditis due to glycopeptide-resistant Enterococcus faecalis in a transplanted heart. Clin Infect Dis. 1993 Sep;17(3):524–525. doi: 10.1093/clinids/17.3.524. [DOI] [PubMed] [Google Scholar]
  33. Williams A. H., Grüneberg R. N. Teicoplanin. J Antimicrob Chemother. 1984 Nov;14(5):441–445. [PubMed] [Google Scholar]
  34. Wilson A. P., O'Hare M. D., Felmingham D., Grüneberg R. N. Teicoplanin-resistant coagulase-negative staphylococcus. Lancet. 1986 Oct 25;2(8513):973–973. doi: 10.1016/s0140-6736(86)90622-7. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES